Skip to main content
Premium Trial:

Request an Annual Quote

Prenatal Testing Startup Juno Diagnostics Closes $25M Series A Financing Round

NEW YORK – Prenatal genetic testing firm Juno Diagnostics said on Wednesday that it has closed an expanded $25 million Series A financing round.

The round was led by the Perceptive Xontogeny Venture Fund. The company said the funding will be used to support clinical validation studies, product development, and commercialization. Juno said in a statement that it generated "a differentiated product offering" and a "collection of promising clinical data" to support the round.

San Diego-based Juno Diagnostics is developing a noninvasive prenatal test using cell-free DNA that "simplifies sample collection and improves access to high-quality genetic testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPT," the firm added.

"With a highly experienced and motivated team, JunoDx is positioned to become the cfDNA testing market leader driven by a sea change in reimbursement and democratizing access via technology innovation," said Chris Garabedian, CEO of Xontogeny and manager of the PXV Fund for Perceptive Advisors.

The company's founders previously worked on developing NIPT at Sequenom.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.